 Agenus Inc NASDAQ: AGEN presented final results from the BalZal combination study at the European Society for Medical Oncology ESMO21 Virtual Conference 2021. Related: Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer. 